Eszopiclone

Generic Name: Eszopiclone

Brand Names: Lunesta

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇ClN_₆O_₃

CAS Number: 138729-47-2

Unique Ingredient Identifier: UZX80K71OE

Background: Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.
...

Indication: Eszopiclone is indicated for the treatment of insomnia.

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 32

Registration Number: NCT00368160

Locations: 🇬🇧
HPRU Medical Research Centre, Guildford, Surrey, United Kingdom

Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

Phase 3

Completed

Conditions: Insomnia
Arthritis, Rheumatoid

Interventions: Drug: placebo
Drug: Eszopiclone

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 153

Registration Number: NCT00367965

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

Phase 3

Completed

Conditions: Insomnia
Depressive Disorder, Major

Interventions: Other: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 545

Registration Number: NCT00368030

Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability

Phase 3

Completed

Conditions: Primary Insomnia

Interventions: Drug: Eszopiclone
Drug: Placebo

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 32

Registration Number: NCT00368056

Locations: 🇬🇧
HPRU Medical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom

Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause

Phase 3

Completed

Conditions: Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-18

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 410

Registration Number: NCT00366093

Study of the Insomnia in Patients With Low Back Pain

Phase 4

Completed

Conditions: Primary Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-18

Last Posted Date: 2015-07-24

Lead Sponsor: Duke University

Target Recruit Count: 58

Registration Number: NCT00365976

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer

Phase 4

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-17

Last Posted Date: 2016-07-11

Lead Sponsor: University of California, San Diego

Target Recruit Count: 45

Registration Number: NCT00365261

Locations: 🇺🇸
UCSD Thornton Hospital, La Jolla, California, United States

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

Phase 3

Completed

Conditions: Primary Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-07-14

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 830

Registration Number: NCT00352144

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone

Phase 3

Completed

Conditions: Parkinson's Disease
Insomnia

Interventions: Other: placebo
Drug: eszopiclone

First Posted Date: 2006-05-11

Last Posted Date: 2013-05-31

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 30

Registration Number: NCT00324896

Locations: 🇺🇸
The New Jersey Neuroscience Institute, Edison,, New Jersey, United States
🇺🇸
University of Pennsylvania Medical School, Philadelphia, Pennsylvania, United States
🇺🇸
Fusion Sleep Center, Suwanee, Georgia, United States

and more 1 locations

Improving Sleep and Psychological Functioning in People With Depression and Insomnia

Phase 4

Completed

Conditions: Sleep Initiation and Maintenance Disorders
Depression

Interventions: Drug: Eszopiclone
Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2005-11-02

Last Posted Date: 2018-08-28

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 60

Registration Number: NCT00247624

Locations: 🇺🇸
Wake Forest University Health Sciences; Department of Psychiatry and Behavioral Medicine, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy